Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-12-15 00:00:00 ET · period of report 2022-12-13 · accession 0000899243-22-038692 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-15 | 2022-12-13 | LGND | Espinoza Octavio | CFO | A - Grant | $0.00 | +11.0K | 18.7K | +143% | $0 |
| D | 2022-12-15 | 2022-12-13 | LGND | Espinoza Octavio | CFO | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-13 | A | A | 11,000 | $0.00 | 18,670 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three equal annual installments on December 5, 2023; December 5, 2024; and December 5, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-12-13 | A | A | 20,000 | $0.00 | 20,000 | D | $63.62 · — to 2032-12-13 | 20,000 Common Stock | (F2) Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter. |